Lifeboat Foundation

MIT engineers have developed a microfluidic device that replicates the neuromuscular junction—the vital connection where nerve meets muscle. The device, about the size of a U.S. quarter, contains a single muscle strip and a small set of motor neurons. Researchers can influence and observe the interactions between the two, within a realistic, three-dimensional matrix.

The researchers genetically modified the neurons in the device to respond to light. By shining light directly on the neurons, they can precisely stimulate these cells, which in turn send signals to excite the muscle fiber. The researchers also measured the force the muscle exerts within the device as it twitches or contracts in response.

The team’s results, published online today in Science Advances, may help scientists understand and identify drugs to treat amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig’s disease, as well as other neuromuscular-related conditions.

Continue reading “New microfluidic chip replicates muscle-nerve connection” »

Engenheiros da University of California, Berkeley construíram os primeiros, sensores sem fio do tamanho de poeira que podem ser implantados no organismo, trazendo mais perto o dia em que um dispositivo Fitbit poderia monitorar os nervos internos, músculos ou órgãos em tempo real.

A universal cancer vaccine is on the horizon after scientists discovered how to rewire immune cells to fight any type of disease.

The potential new therapy involves injecting tiny particles of genetic code into the body which travel to the immune cells and teach them to recognise specific cancers.

Although scientists have shown previously that is it is possible to engineer immune cells outside the body so they can spot cancer it is the first time it has happened inside cells.

Continue reading “Universal cancer vaccine on horizon after genetic breakthrough” »

Nice.

When we think of synthetic biology, we often think of engineering a cell to give it some useful function. But SEED 2016 had quite a few speakers working outside of a biological cell. Some broke open cells to utilize just the cellular machinery to create “cell-free” systems. Others showed what could be done inside of the computer (in silico) to improve our understanding and prediction of synthetic gene networks. Here, we’re highlighting SEED speakers who showed how both of these approaches can advance synthetic biology.

Cell-free synthetic biology

Continue reading “SEED 2016: What can we do outside of a cell?” »

Tempus fugit. I’m just about old enough to remember a time in which 2020 was the distant future of science fiction novels, too far away to be thinking about in concrete terms, a foreign and fantastical land in which anything might happen. Several anythings did in fact happen, such as the internet, and the ongoing revolution in biotechnology that has transformed the laboratory world but leaks into clinics only all too slowly. Here we are, however, close enough to be making plans and figuring out what we expect to be doing when the third decade of the 21st century gets underway. The fantastical becomes the mundane. We don’t yet have regeneration of organs and limbs, or therapies to greatly extend life, but for these and many other staples of golden age science fiction, the scientific community has come close enough to be able to talk in detail about the roads to achieving these goals.

Of all the things that researchers might achieve with biotechnology in the near future, control over aging is by far the most important. Aging is the greatest cause of death and suffering in the world, and none of us are getting any younger. That may change, however. SENS, the Strategies for Engineered Negligible Senescence, is a synthesis of the scientific view of aging as an accumulation of specific forms of cell and tissue damage, pulling in a century of evidence from many diverse areas of medical science to support this conclusion. Aging happens because the normal operation of our cellular biochemistry produces damage, wear and tear at the level of molecules and molecular structures, and some of that damage accumulates to cause failure of tissues and organs, and ultimately death.

Philadelphia, PA, USA / Mexico City, Mexico — Bioquark, Inc., (www.bioquark.com) a life sciences company focused on the development of novel bioproducts for complex regeneration, disease reversion, and aging, and RegenerAge SAPI de CV, (www.regenerage.clinic/en/) a clinical company focused on translational therapeutic applications of a range of regenerative and rejuvenation healthcare interventions, have announced a collaboration to focus on novel combinatorial approaches in human disease and wellness. SGR-Especializada (http://www.sgr-especializada.com/), regulatory experts in the Latin American healthcare market, assisted in the relationship.

“We are very excited about this collaboration with RegenerAge SAPI de CV,” said Ira S. Pastor, CEO, Bioquark Inc. “The natural synergy of our cellular and biologic to applications of regenerative and rejuvenative medicine will make for novel and transformational opportunities in a range of degenerative disorders.”

As we close in on $7 trillion in total annual health care expenditures around the globe ($1 trillion spent on pharmaceutical products; $200 billion on new R&D), we are simultaneously witnessing a paradoxical rise in the prevalence of all chronic degenerative diseases responsible for human suffering and death.

Continue reading “Bioquark Inc. and RegenerAge SAPI de CV to Collaborate on Clinical Regenerative Healthcare” »

A new method for medicine.

Imagine a cross between one of those multi-color retractable pens and an epi-pen. But instead of colors, the device would have different medications. Now combine this with a tiny, droplet-sized sweatshop full of obedient single-celled organisms genetically engineered to produce those medications, and you’ve got what a team from MIT just published in Nature Communications: A new project, with funding from DARPA, that has demonstrated the ability to synthesize multiple medications on-demand and as-needed using yeast. The discovery could soon revolutionize our ability to deliver medicine after natural disasters or to remote locations.

Let’s stick with the metaphor of an epi-pen. First, the user presses the actuator, which mixes a chemical trigger into a culture of engineered Pichia pastoris cells. Upon exposure to certain chemical triggers, the cells are programmed to produce a protein: in the report, the team used estrogen β-estradiol, which caused the cells to express recombinant human growth hormone (rHGH), and also methanol, which induced the same culture of yeast to make interferon. By controlling the concentration of the chemical trigger and the population of P. pastoris, the team demonstrated that they could make their device produce a dose of either interferon or rHGH on command. To switch between products, they just pushed another button on the microbioreactor, which flushes out the cell culture with clean, sterile fluid.

Continue reading “Portable bioreactor from MIT produces medications, vaccines on-demand” »

AWESOME.

New UCLA research suggests that a gene-based immunotherapy that has shown promising results against cancer could also be used against HIV, the virus that causes AIDS.

In a study to be published in an August issue of the bi-monthly peer-reviewed Journal of Virology, researchers with the UCLA AIDS Institute and Center for AIDS Research found that recently discovered potent antibodies can be used to generate chimeric antigen receptors, or CARs, that can be used to kill cells infected with HIV-1.

Continue reading “Promising Cancer-Fighting Gene Immunotherapy Could Be Used Against HIV, UCLA Research Suggests” »

A Yale research team has designed a system to modify multiple genes in the genome simultaneously, while also minimizing unintended effects. The gene-editing “toolbox” provides a user-friendly solution that scientists can apply to research on cancer and other disciplines, according to a news release from Yale.

The study was published on July 26 in Nucleic Acids Research.

The news release states that, with modern genetic engineering techniques, researchers can edit genes in experiments. This allows researchers to study important disease-related genes and may ultimately allow them to treat genetic diseases by making edits in specific sites of the human genome. However, progress has been hampered by several challenges, including the editing of unintended sites — referred to as off-target effects.

Continue reading “Yale team designs gene modification system” »